| Title | Licenses; Exemptions, Applications, Amendments etc.: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies That Are Specific to CD22 and Other B-Cell Antigens for the Treatment of B-Cell Malignancies |
| ToC Doc | Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies That Are Specific to CD22 and Other B-Cell Antigens for the Treatment of B-Cell Malignancies |
| Docket Number | 2022-04245 |
| Type | Notice |
| Subject | Licenses; Exemptions, Applications, Amendments etc.: Development and Commercialization of Chimeric Antigen Receptor T-Cell Therapies That Are Specific to CD22 and Other B-Cell Antigens for the Treatment of B-Cell Malignancies |
| Publication Date | 2022-03-01 |
| Last Updated Date | 2022-02-28 08:15:11 -0500 |
| Last Public Inspection | 2022-02-28 |
| Filed At | 2022-02-28T08:45:00.000-05:00 |
| 2022-04245_PI.pdf (94552 bytes) | |
| Download | TXT / HTML / JSON |
| Number of Pages | 7 |
| Filing Type | regular |
| Agencies | National Institutes of Health |
You can find the raw source document below...